Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights March 24, 2020 • 5:15 PM EDT
Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit March 23, 2020 • 4:30 PM EDT
Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering March 3, 2020 • 5:00 PM EST
Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market February 28, 2020 • 8:45 AM EST
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800) February 26, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering February 11, 2020 • 4:01 PM EST
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD February 5, 2020 • 5:15 PM EST
Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences February 4, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference January 29, 2020 • 4:15 PM EST
